Janus kinase inhibitor - Wikipedia
JAK enzymes are part of the JAK/STAT pathway. This signaling pathway transmits chemical signals from the outside of cells, specifically lymphocytes, and into the cell nucleus.
What are JAK inhibitors and how do they work? - Drugs.com
Jul 15, 2025 · Janus kinase (JAK) inhibitors are a group of medicines that help block immune system signals in the body that can lead to swelling (inflammation) and pain in conditions like …
JAK Inhibitors: Uses, Types, Side Effects, and More
Aug 23, 2025 · In this article, learn about the dosage, uses, and ongoing research underway for JAK inhibitors available in the United States, as well as common side effects, …
JAK inhibitors: an evidence-based choice of the most appropriate ...
Recently, Janus kinase inhibitors (JAKi) have been developed to block the effect of proinflammatory cytokines in IMIDs.
JAK Inhibitors 101 - The Rheumatologist
Jul 28, 2025 · The JAK-signal transducer and activator of transcription (STAT) pathway is central to immune dysregulation in many autoimmune diseases due to its role in transducing signals …
Understanding the Mechanism of Action in JAK Inhibitors
Jun 2, 2024 · Jason Hawkes, MD, MS, medical dermatologist in Sacramento, California presented an in-depth overview on the mechanism of action (MOA) of Janus Kinase (JAK) inhibitors, a …
List of the 9 Leading JAK Inhibitor Drugs - GoodRx
Aug 13, 2024 · Janus kinase (JAK) inhibitors are a group of medications with many uses. Rinvoq (upadacitinib), Xeljanz (tofacitinib), and Cibinqo (abrocitinib) are options for eczema and other …
JAK Inhibitors: Uses, Benefits, and Side Effects Explained
Janus kinase (JAK) inhibitors are a class of medications used to treat autoimmune and inflammatory conditions such as rheumatoid arthritis, psoriasis, and certain types of eczema. …
Pharmacological targeting of the JAK–STAT pathway: new
Jan 5, 2026 · The Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway mediates cellular responses to cytokines and growth factors, and its dysregulation …
FDA-Approved JAK Inhibitors in Myelofibrosis: Mechanisms, …
3 days ago · Four JAK inhibitors—ruxolitinib, fedratinib, pacritinib, and momelotinib—are FDA-approved for the treatment of myelofibrosis, each with nuanced differences in clinical …